thrombophilic state, history of previous thrombotic events, and hypotension in the intraoperative or postoperative period. 3 Other significant risk factors include type of preservation solution (reduced risk with UW), prolonged cold ischemia time (CIT), and technical factors during procurement and implantation. 2, 7 Rate of graft loss secondary to PAT has been reported as 4% to 8% after simultaneous pancreaskidney transplantation (SPK) and 10% to 12% after solitary pancreatic transplantation (SPT). 8 Imaging plays a vital role in the evaluation of the transplanted pancreas. The modalities commonly used are Doppler ultrasound (USS), contrast-enhanced ultrasound (CEUS), computed tomography (CT), CT angiography, magnetic resonance imaging (MRI), and MR angiography. [9] [10] [11] [12] Vascular evaluation on imaging after pancreas transplantation is challenging due to the multiple anastomoses (4 or more), tortuous nature of graft vessels, and parenchymal edema related to surgery or pancreatitis. Overlying bowel gas may make ultrasound imaging suboptimal. [13] [14] [15] Allograft thrombosis may affect arteries or veins, or sometimes both. Although there is no consensus on the classification or reporting of PAT, it is generally categorized as either complete or partial. 16 Complete occlusion usually results in graft loss, unless thrombectomy or thrombolysis are undertaken soon after onset. [17] [18] [19] [20] Conversely, there is some evidence to suggest a higher likelihood of pancreas allograft salvage with anticoagulation alone after partial thrombosis, although other interventions are occasionally required. 21, 22 Outcomes after partial or complete occlusion of either splenic or superior mesenteric veins are better than complete occlusion of the main portal vein. 23 Collateral arterial circulation may prevent infarction in cases of partial and occasionally complete PAT. 24 There is currently no consensus on the optimal strategy for the prevention and management of PAT. Postoperative prophylaxis using low-dose heparin infusion has been shown to reduce the thrombosis rate, but with a consequent increase in the number of bleeding events and need for repeat laparotomy. [25] [26] [27] The aims of the current study were to analyze the incidence and management of PAT in a single center and to evaluate risk factors for F I G U R E 1 Representative cross-sectional images demonstrating grades 1-3 of venous and arterial pancreas allograft thrombosis. IMAGE 1: Grade 1 venous thrombus: axial image of a portal phase study demonstrating non-occlusive thrombus (arrow) within an SMV tributary within fat, at the transected margin of the graft. IMAGE 2: Grade 2 venous thrombus: coronal reformatted image of a portal phase study demonstrating non-occlusive thrombus extending along the splenic vein within the body of graft pancreas (arrow). Adjacent patent splenic artery (short arrow). IMAGE 3: Grade 3 venous thrombus: unenhanced axial image demonstrating acute hyper-dense thrombus in an expanded SMV. IMAGE 4: Grade 3 venous thrombus: portal phase axial image demonstrating thrombus in the SMV extending into the IVC (arrow). This component is seen as hypo-dense within otherwise opacified cava. IMAGE 5: Grade 1 arterial thrombus: axial arterial phase image demonstrating minimal thrombus in the distal splenic artery (arrow). IMAGE 6: Grade 2 arterial thrombus: axial arterial phase image demonstrating thrombus extending into the mid SMA. IMAGE 7: Grade 3 arterial thrombus: (image not from current series; obtained from a library) arterial phase coronal reformatted image demonstrating acute occlusive thrombus expanding the Y graft and SMA (arrow). Enhancement of the residual patent proximal Y graft stump (short arrow)
PAT. We also propose a CT grading system of PAT and a management algorithm based on the grade of thrombosis.
| MATERIALS AND METHODS
After institutional review board approval, a retrospective review was carried out of consecutive pancreas allograft transplants performed at our center between January 2009 and April 2014. Data regarding donor and recipient demographics, operative details, and outcomes were collected from a prospectively maintained electronic database.
The outcomes reviewed were the incidence of PAT, graft and patient survival, postoperative complications, and length of postoperative hospital stay. Patients had workup for prothrombotic tendencies if a prior thrombotic event was identified.
The incidence, risk factors, and consequences of PAT were examined through the use of 2 methods. The first was a retrospective review of clinical data as recorded in the database during the original patient care episode, including incidence of thrombosis and graft and recipient outcomes (labeled "original diagnosis"). In the second stage, the first postoperative triple-phase CT of the abdomen and pelvis (CTAP) of all pancreas transplant recipients were independently reviewed by 2 senior radiologists who were blinded to the initial CT report and the patient outcomes. Discrepancies were resolved by consensus. This "retrospective diagnosis" was used to definitively grade the thromboses and to formulate a management algorithm.
The pancreatic allograft arteries and veins were graded as per the "new" grading system (Table 1) . Representative cross-sectional images demonstrating the different grades of thrombosis are shown in Figure 1 .
Acute rejection was defined as rejection on kidney or pancreas biopsy. Graft pancreatitis was defined as peripancreatic edema and/or inflammatory change on CT scanning.
| Operative technique
Back-bench preparation of the pancreatic graft involved removal of spleen, ligation of all the distal mesenteric vessels, and anastomosis of a donor iliac Y-graft to the graft superior mesenteric and splenic arter- 
| CT scanning
Triple-phase CTAP was performed using 64-or 256-section CT systems (Siemen AG Healthcare, Camberley, Surrey, UK). Unenhanced imaging of the abdomen was performed to localize the pancreatic graft, followed by early arterial phase imaging of the pancreatic and renal grafts and portal phase imaging of the abdomen and pelvis. We administered 100 mL of iopamidol nonionic contrast (Niopam 300;
Bracco, High Wycombe, Bucks, UK) at a rate of 3 mL per second.
Images were reconstructed and reviewed at 2-mm section thickness on the picture archive and communication system (PACS GE). The triple-phase CT scans were performed for clinical/biochemical reasons, and no routine or protocol scans were performed. Intravenous fluid rehydration was considered in recipients with a raised creatinine of greater than 150 μmol/L. Routine USS is performed to evaluate the renal allograft; routine USS of the pancreatic graft is not performed in our unit. 
| Statistical analysis

| RESULTS
One hundred three consecutive pancreatic transplantations were performed during the study period. The mean follow-up period was 
| Donor characteristics
There was no difference between the 2 groups in terms of donor age, sex, ethnicity, weight, and BMI (Table 2 ). There were numerically more donation after brainstem death (DBD) donors in the thrombosis group (n = 19, 79.2%) compared with the no-thrombosis group (n = 50, 63.3%), but this was not statistically significant (P = .107).
| Recipient characteristics
There was no difference between the 2 groups in terms of recipient age, sex, weight, BMI, or previous thrombotic events (Table 3) . Three .349
T A B L E 3 Recipient characteristics
Continuous variables are expressed as median (ranges) and categorical variables as frequencies (percentages). DVT, deep vein thrombosis; PE, pulmonary embolism; SPK, simultaneous pancreas-kidney transplant.
| Operative characteristics
In total, 4 (80%) of 5 pancreas after kidney or SPK (PAK/PASPK) transplants had thrombosis post-operatively (P < .001) ( Table 4 ). Only 1 recipient had portal vein reconstruction at the time of transplantation using an 8-mm extension graft; he subsequently developed portal venous thrombosis. Two (8.3%) patients in the thrombosis group had intraoperative thrombosis, and the portal vein anastomoses were redone, in comparison to 1 patient (1.3%) in the no-thrombosis group in whom the arterial anastomosis was redone (P = .135).
| Recipient outcomes
Recipient outcomes for the 2 groups are shown in Table 5 Number of patients given in brackets. *P value considered to be significant if <.025 (Bonferroni corrected 0.05/2 = 0.025). P values that are significant are highlighted in bold. patient, who was noted to be at high risk of venous thrombosis at the initial implant surgery and was anticoagulated in the immediate postoperative period, was reexplored on postoperative day 1 with removal of splenic vein thrombus. With continuing hyperglycemia and worsening lactate, the patient was reexplored again at 48 hours posttransplantation, and graft pancreatectomy was performed.
T A B L E 4 (Continued) T A B L E 5 Recipient outcomes
All patients with an original diagnosis of thrombosis were therapeutically anticoagulated with dalteparin (140 units/kg/day split into 2 doses at 12-hour interval) in the first instance followed by warfarin for a period of 3 months (target INR 2-2.5). Patients who underwent reexploration were anticoagulated after exploration surgery, unless graft pancreatectomy (3 patients) was performed.
There were no contrast-induced allergic reactions in our study cohort. Eighty-one patients had at least 1 postoperative CT during the study period. Serial creatinine results were available for 67 of these patients. Twelve patients had an acute rise in creatinine after CT scans, in keeping with contrast-induced acute kidney injury (CI AKI), although 7 patients were receiving dialysis at the time. An alternative possible explanation for the rise in creatinine was identified in all 5 patients: 1 patient was diagnosed with rejection, 1 with hemorrhage, 1 with renal arterial flow abnormality on USS, and 2 with abdominal pain ± pyrexia.
Renal function recovered in all 12 patients with rehydration.
| Arterial thrombosis
One patient with grade 1 arterial thrombosis and extrinsic compression of the portal vein on CT was reexplored and no thrombus was seen within the artery, but there was severe pancreatitis of the al- 
| Venous thrombosis
All patients with grade 1 (n = 5) venous thrombosis were anticoagulated and had functioning grafts at the end of study follow-up. The only patient who had a PV extension graft had a CT diagnosis of grade 2 venous thrombosis on postoperative day 5. Reexploration and thrombectomy .436** Continuous variables are expressed as median (range) and categorical variables as frequencies (percentages). AIHA, autoimmune hemolytic anaemia; CPR, cardiopulmonary resuscitation; CT, computed tomography; GI, gastrointestinal; PE, pulmonary embolism; PID, pelvic inflammatory disease; PV, portal vein; RBC, red blood cell; SBO, small bowel obstruction; USS, ultrasound scan; VAC, vacuum therapy; VRE, vancomycin-resistant Enterococcus. *P value considered to be significant if <.025 (Bonferroni corrected 0.05/2 = 0.025). P values that are significant are highlighted in bold. **Log-rank (Mantel-Cox) P value from survival analysis.
did not improve graft perfusion, and pancreatectomy was performed.
Another patient with grade 2 venous thrombosis was reexplored on postoperative day 1 and portal vein thrombus was removed; the graft was functioning at the end of study follow-up. One other patient with grade 3 venous thrombosis on CT scanning on postoperative day 3 was managed with anticoagulation initially but was reexplored on day 9 due to hemorrhage and the graft was subsequently removed on day 11 due to severe hemorrhage and PVT. All other patients with grade 2 (n = 1) and 3 (n = 2) venous thrombosis were managed with anticoagulation and had a functioning graft at the end of study follow-up.
| Postoperative complications and length of hospital stay
Eight (33.3%) patients in the thrombosis group were reexplored for bleeding (3 preanticoagulation and 5 postanticoagulation patients), whereas 12 (15.2%) were reexplored for bleeding in the control (no thrombosis) group (P = .074). There were 21 early (within 30 days) complications in 13 patients in the thrombosis group and 39 complications in 31 patients in the control group (P = .241) ( Table 5 
| Risk factors for PAT
On multivariate analysis, PASPK/PAK transplant (odds ratio [OR]
1.09, confidence interval [CI] 1.01-0.97, P = .047), acute rejection (OR 1.25, CI 1.07-1.90, P = .034), and CT finding of pancreatitis (OR 1.23, CI 1.08-1.72, P = .011) were risk factors for PAT (Table 6 ). The risk of vascular thrombosis was 9% higher with PASPK/PAK transplant in comparison to SPK transplant, 25% higher when there was acute rejection (although most cases of thrombosis were diagnoses early and before the diagnosis of rejection), and 23% higher when there were CT findings of allograft pancreatitis.
| Graft and patient survival
There were 6 (25.0%) graft losses in the thrombosis group with 3 grafts lost within 30 days due to portal vein thrombosis resulting in graft pancreatectomy on days 2, 5, and 11. The other 3 graft losses were due to severe pancreatitis with abscess formation in 1 patient and biopsy-proved chronic rejection in 2 patients. There were 3 (3.8%) graft losses in the control group, 2 due to chronic rejection and 1 due to recurrence of "autoimmune" diabetes mellitus ( Table 5) . The 1-, 3-, and 5-year death-censored graft survival for thrombosis and nothrombosis groups were 75%, 75%, and 75% vs 100%, 90%, and 90%, respectively (log-rank P < .0001) (Figure 2 ). There was no difference in patient survival between the 2 groups (1-, 3-, and 5-year rates were 98%, 96%, and 94% in each group) (Figure 3) . None of the patient deaths in the study groups were directly related to PAT (Table 5 ).
| Risk factors for graft loss
On univariate analysis, recipient anastomosis time (48 ± 11 minutes in graft loss group vs 38 ± 9 minutes in control group; P = .001) and PAT (66.7% in graft loss group vs 19.1% in control group; P = .005) were statistically significant predictors of graft loss. On multivariate analysis, PAT was the only significant risk factor for graft loss (OR 1.17, 95% CI 1.04-1.83, P = .028).
| Independent retrospective review of CT scans
During the study period, 81 CT examinations were reported during the index admission. In total, 16 different senior radiologists reported the CT scans over the study period. On independent review of the CTs, previously unreported thromboses (additional thromboses) were identified by both review radiologists. In consensus, the review (Table 7) . Four patients who were initially reported to have thrombosis were subsequently reviewed as having no thrombosis. The risk of vascular thrombosis was 9% higher with PASPK/PAK transplant in comparison to SPK transplant, 25% higher when there was acute rejection, and 23% higher when there were CT findings of allograft pancreatitis. P values that are significant are highlighted in bold. CI, confidence interval; CT, computed tomography; OR, odds ratio; PAK, pancreas after kidney transplant; SPK, simultaneous pancreas-kidney transplant.
a Logistic regression analysis.
T A B L E 6 Risk factors for allograft thrombosis F I G U R E 2 Death-censored graft survival. Graft survival was significantly inferior in the thrombosis group compared to controls. All graft losses in this group occurred within two weeks of transplantation F I G U R E 3 Patient survival. There was no difference in patient survival between thrombosis and no-thrombosis groups A total of 28 new thromboses were identified on retrospective review of the CT scans. Four patients who were initially reported to have thrombosis were subsequently reviewed as having no thrombosis. P values are comparison between 2 groups: Column 1: T-AC (all grades of thrombosis) vs T-NAC; Column 3: T-AC (grade 1 and 2 thromboses only) vs T-NAC. P values that are significant are highlighted in bold. AC, anticoagulated; NAC, not anticoagulated; NT, no thrombosis; T, thrombosis.
The thrombosis grade for these 4 patients on initial reports were grade 1 arterial, grade 3 arterial, and 2 patients with grade 1 venous.
Using the new retrospective diagnoses, we repeated the earlier analysis that is shown in Tables 1-4 using the original diagnoses. Univariate analysis comparing those who had thrombosis on retrospective CT review (n = 53) with those who had no thrombosis (n = 28) demonstrated no significant predisposing factors for thrombosis (Tables S1-S4 ).
| Outcomes based on retrospective review of CT scans
Based on the retrospective review, patients were divided into 4 distinct groups according to the presence or absence of thrombosis (as a consensus of radiologists 1 and 2) and whether the recipients were anticoagulated. The retrospective review gave us an opportunity to compare outcomes in these groups, in a manner that would not be possible prospectively outside of a randomized controlled trial.
Moreover, if we assume that the "new" thromboses diagnosed only on retrospective review were originally not reported at random, this approach reduces (but does not eliminate) bias.
Twenty-six patients were identified to have thrombosis on retrospective CT review but were previously not anticoagulated (T-NAC).
Eighteen patients with thrombosis on retrospective review were an- 2 grafts lost in the T-AC group due to portal vein thrombosis (Table 8 and Figure 4) . RetrospecƟve review of CT images (n=81)
ticoagulated (T-AC
GraŌ loss -0 Median Length of stay -17 days P = .374). There was no graft loss due to thrombosis in those with T-NAC and T-AC with grade 1 and 2 thromboses only (Table 8 ). There was also no difference in graft and patient survival on comparing those who were anticoagulated for grade 1 and 2 thrombosis and those who were not anticoagulated ( Figures 5 and 6 ).
Based on these findings, an algorithm for the management of thrombosis based on new CT grading system is presented in Figure 7 .
| Evolution of thrombosis on retrospective review of CT scans
To determine if anticoagulation influences the evolution of grade 1 and 2 thromboses, we compared late CT images in the T-AC and TNAC groups ( Table 9 ). Retrospective review of CT images at 3 months of those who were anticoagulated for thrombosis demon- 
| DISCUSSION
The incidence of PAT in our center is 23.3% (n = 24). The rate is high because we have included grade 1 thrombosis (peripheral thrombus), which forms a majority of our thromboses (45.8%; n = 11).
We believe many of these are not reported in previous publications. Only 5.8% of recipients in our series were diagnosed with occlusive (grade 3) thrombosis. Moreover, the incidence of graft loss secondary to thrombosis was only 2.9%. 5, 28 While managements of recipients with PAT must be primarily based on individual clinical circumstances, we believe that our analysis can potentially inform and enhance evidence-based clinical decision-making. Based on our proposed grading system, henceforth termed the Cambridge Pancreas Allograft Thrombosis (CPAT) grading, our data suggest that grade 1 and 2 arterial thromboses and grade 1 venous thrombosis can be managed safely without formal anticoagulation. Although we report 17% higher risk of graft loss with thrombosis, all of the graft losses in our cohort were due to grade 2 or 3 thrombosis and F I G U R E 5 Death-censored graft survival. Graft survival was similar between thrombosis-Anticoagulated (Grade 1 and 2) and Thrombosis-Not anticoagulated groups grade 1 thrombosis had no effect on graft or patient survival. The risk factors for PAT in our cohort were pancreas transplantation into a nonuremic patient, acute rejection, and pancreatitis on CT, similar to previous published literature. 29, 30 The important findings from our study are that arterial throm- transplantations over a 7-year period, reported a negative laparotomy rate of 43%. 18 The proposed CPAT grading system helps clinicians make decisions on which grafts may require reexploration and which can be managed with anticoagulation alone. The retrospective review of the CT scans allowed us to compare 2 groups -one therapeutically anticoagulated for grade 1 and 2 thromboses and one managed conservatively. Because the diagnoses of thrombosis in the nonanticoagulated group were not reported at random, this reduces potential bias arising from allocation of patients to the 2 groups. In this study, therefore, patients were in effect "inadvertently randomized" into anticoagulation and conservative groups at the time of the index admission. Importantly, we were able to compare outcomes in the 2 groups where the CPAT grades of the thrombosis were compa- Although the CPAT grading system has been used to report CT studies, we believe the same grading system could be applicable for USS or CEUS or MR reporting of PAT.
Management of PAT without anticoagulation (except aspirin) has been reported previously with no deleterious effects on the graft.
Ciancio et al. reported 6 patients with partial PAT of the splenic vein, who were started on aspirin 81 mg once daily and followed with serial Doppler USS. None progressed to complete thrombosis, and all had a functioning graft at the end of follow-up. 31 Delis et al. managed partial venous thrombosis (n = 10) with aspirin alone and showed no progression of thrombosis. They reported recanalization of the thrombosed veins on follow-up imaging and, overall, there was no effect on graft survival. 32 Our retrospective review of images at 3 months and subsequently showed that majority of patients who were not anticoagulated for thrombosis had a reduction in grade of thrombosis to no thrombosis or lower grade thrombosis. This is in keeping with our suggestion that formal anticoagulation with LMWH is unnecessary in grade 1 and 2 arterial and grade 1 venous thromboses. Thromboelastographydirected anticoagulation may have a role in identifying patients who need anticoagulation in the postoperative period. 33 The major strength of our study is the inclusion of unselected, consecutive patients from a single center. The retrospective nature 
| CONCLUSION
This retrospective study reports findings that suggest thromboses that do not involve the central vessels (portal vein or Y-graft) of pancreatic grafts (grade 1 or grade 2) can be managed without anticoagulation.
The proposed CPAT grading system may help reporting of thrombosis, provide prognostic information for the individual patient, and allow better comparison of reports from different centers for improved understanding and management of this common condition. Future studies should focus on reporting outcomes when partial thrombosis is managed without anticoagulation. Prospective studies are needed to verify the suggested protocol, and ascertain the evolution of allograft thrombosis when the patients are anticoagulated, and to determine the optimal duration of anticoagulation.
